Ray Reports 24.5 Billion KRW in Q1 Revenue... "Record-High Quarterly Performance"

On May 13, Ray announced that it had achieved its highest-ever quarterly revenue since its establishment and, for the first time in the company's history, surpassed the break-even point (BEP) in the first quarter.

Ray reported consolidated revenue of 24.5 billion KRW in the first quarter, marking a 40% increase compared to the same period last year. Operating profit reached 200 million KRW, successfully turning a profit. Net income also returned to positive territory. This is the first time since the company's founding that it has achieved this in the first quarter. A company representative stated, "This achievement is even more significant because it was accomplished in the first quarter, which is typically considered a seasonal off-peak period," and added, "It is not simply a temporary rebound in demand, but rather an indicator that the company's profit structure is fundamentally improving."

Ray expects its improved performance to continue throughout this year. The market environment in its major export countries is gradually turning around. Orders are recovering in advanced medical markets such as the United States, Japan, and Taiwan. Demand for the product categories that Ray has strategically strengthened is also rebounding rapidly.

A company representative explained, "We are still taking a conservative approach to the Chinese market, but last year represented the bottom, and we are now seeing signs of recovery," and added, "If demand in China recovers more than expected, there is a strong possibility that we will exceed our currently projected annual growth rate."

The product expected to further drive Ray's future performance momentum is the 'Rayquantum 5D.' This product is currently in the final stages of the U.S. FDA certification process. Once certification is obtained, full-scale sales in the U.S. market are expected to begin.

The representative emphasized, "'Rayquantum 5D' has received evaluations from clients that exceed expectations in its initial feedback," and added, "If full-scale sales begin, there is a possibility that we may raise our overall performance guidance."

Ray is currently restructuring its organization. The company is diversifying its product portfolio compared to the past and focusing on improving margins. As part of this diversification, Ray has established an AI-based platform. Through this platform, users can seamlessly translate accurate and easy diagnosis and treatment planning into treatment outcomes. The new AI solution is expected to contribute to additional new revenue as it obtains certifications in each country, starting with the FDA, followed by the Japanese Ministry of Health certification in July, and Taiwanese certification in September.

A company representative stressed, "The structural changes have been reflected in this first quarter's results," and added, "With a structure that does not carry a heavy fixed cost burden, increased sales can lead to a significant operating leverage effect."